Skip to main content
. 2013 May;57(5):2054–2065. doi: 10.1128/AAC.02494-12

Table 3.

Variant persistence in HCV patients after treatment QD with 1 mg of DCV by population sequence

Patient Genotype Time RNA (IU/ml) Substitution(s) (% frequency)a
Additional mutation (% frequency)
M/L28 Q/R30 L31 Y93
A 1a T0 1.1E+06 WT WT WT WT
T12 2.1E+03 WT WT WT WT
Day 14 3.9E+05 T (∼45%, ∼45%) H (∼10%, ∼10%), R (∼30%, ∼10%) M (0, ∼30%) C (0, ∼20%)
Day 15 7.9E+05 T (∼35%) H (∼2.5%), R (∼40%) M (∼10%) C (∼15%)
Day 21 6.3E+05 T (∼30%) H (∼7.5%), R (∼40%) M (∼20%) C (∼7.5%)
Day 28 2.0E+06 T (∼25%) H (∼5%), R (∼40%) M (∼12.5%) C (∼5%)
Day 42 3.2E+06 T (∼27.5%) H (∼5%), R (∼40%) M (∼20%)
B 1a T0 3.2E+05 WT WT WT WT H58P (∼5%)
Day 14 7.9E+04 T (∼10%) R (∼5%) M (∼50%) H58P (∼55%)
Day 15 1.0E+05 T (∼10%) R (∼10%) M (∼50%) H58P (∼20%)
Day 21 3.2E+05 T (∼10%) R (∼7.5%) M (∼35%) H58P (∼5%)
Day 28 1.3E+06 T (∼7.5%) R (∼5%) M (∼37.5%) T21I (∼5%)
Day 42 3.2E+06 T (∼5%) H (∼10%), R (∼5%) M (∼60%) T21I (∼7.5%)
Day 98 1.6E+06 T (<2.5%) H (∼10%) M (∼77.5%) T21I (∼25%)
Day 182 1.3E+05 T (<5%) H (∼7.5%) M (∼90%) T21I (∼50%), H58P (∼52.5%)
C 1b T0 5.4E+04 WT WT WT WT
Day 4 <25 ND ND ND ND
Day 7 Undetectable ND ND ND ND
Day 15 Undetectable ND ND ND ND
Day 21 Undetectable ND ND ND ND
Day 28 Undetectable ND ND ND ND
Day 42b 1.0E+02 WT WT WT WT
Day 98 1.0E+04 WT WT WT WT
D 1b T0 5,765 WT WT WT WT
Day 7 <25 ND ND ND ND
Day 14 Undetectable ND ND ND ND
Day 15 Undetectable ND ND ND ND
Day 21 Undetectable ND ND ND ND
Day 28 Undetectable ND ND ND ND
a

Frequencies are quantitative estimates of variants based on chromatograms from population sequencing (estimated from the average of two PCR products). “WT” indicates consensus with the WT. ND, not determined (HCV RNA < 1,000 IU/ml). Data for T0 to day 14 have been reported previously (3, 4).

b

Data derived from one PCR product.